表皮坏死松解症患者死亡预后评估的改进:新型炎症标志物的作用及SCORTEN修订建议(Re-SCORTEN)
该回顾性队列研究纳入2003至2019年新加坡中央医院196例表皮坏死松解症患者,最终分析192例,院内死亡43例(22.4%)。校正SCORTEN后仅红细胞分布宽度与血红蛋白比值(RDW/Hb)可显著预测院内死亡(OR 3.55;95%CI 1.76-7.16;P<.001)。RDW/Hb加入SCORTEN形成的Re-SCORTEN较SCORTEN单独判别力显著更优(AUC 0.83 vs 0.78,P=.02)。
要点
- 192例表皮坏死松解症患者中43例(22.4%)院内死亡。
- 校正SCORTEN后RDW/Hb预测院内死亡OR 3.55(95%CI 1.76-7.16;P<.001)。
- Re-SCORTEN较SCORTEN判别力更优(AUC 0.83 vs 0.78,P=.02)。
核心结论
- 在该队列中,RDW/Hb作为一种廉价易得的标志物,其预测准确性与SCORTEN相似。
- RDW/Hb与SCORTEN联合使用有助于提升预后评估能力。
研究设计与样本
- 回顾性队列研究,时间跨度为2003年至2019年共17年。
- 患者来自新加坡中央医院(表皮坏死松解症国家转诊中心),共招募196例,其中4例(2%)因数据不完整被排除。
- 最终分析192例患者,中位年龄56岁(IQR 42-70),女性114例(59.4%)。
主要发现
- 192例患者中43例(22.4%)未存活至出院。
- 在新型炎症标志物中,仅RDW/Hb在校正SCORTEN后对院内死亡预测显著(OR 3.55;95%CI 1.76-7.16;P<.001)。
- RDW/Hb按4个风险分组应用时,其判别力与SCORTEN相似(AUC:RDW/Hb 4组0.76[95%CI 0.69-0.84] vs SCORTEN 0.78[95%CI 0.70-0.85],P=.89)。
- RDW/Hb加入SCORTEN后,复合评分Re-SCORTEN的判别力显著优于SCORTEN单独使用(AUC:Re-SCORTEN 0.83[95%CI 0.77-0.89] vs SCORTEN 0.78[95%CI 0.70-0.85],P=.02)。
- 总体NRI为0.94(95%CI 0.68-1.20),P<.001;IDI为0.06(95%CI 0.03-0.08),P<.001;Re-SCORTEN在校准图上显示良好校准。
关键数值与推荐
- RDW/Hb预测院内死亡的OR 3.55(95%CI 1.76-7.16;P<.001),校正SCORTEN后。
- RDW/Hb 4组AUC 0.76(95%CI 0.69-0.84)vs SCORTEN AUC 0.78(95%CI 0.70-0.85),P=.89。
- Re-SCORTEN AUC 0.83(95%CI 0.77-0.89)vs SCORTEN AUC 0.78(95%CI 0.70-0.85),P=.02。
- NRI 0.94(95%CI 0.68-1.20),P<.001;IDI 0.06(95%CI 0.03-0.08),P<.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Epidermal necrolysis is a severe cutaneous adverse reaction in which severe systemic inflammation results in extensive epithelial keratinocyte necrosis. The most commonly used prognostic score in epidermal necrolysis, the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN), was recently found to overestimate mortality in contemporary cohorts. Identification of independent prognostic markers may help to stratify risk more accurately. OBJECTIVE: This study evaluates the association between novel inflammatory markers and in-hospital mortality in patients with epidermal necrolysis to study the incremental prognostic value of these markers in combination with SCORTEN. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted over a 17-year period from 2003 to 2019. Patients were enrolled from Singapore General Hospital, the national referral center for epidermal necrolysis. A total of 196 patients with epidermal necrolysis were recruited, 4 (2%) of whom were excluded owing to incomplete data. MAIN OUTCOMES AND MEASURES: The main outcome assessed was the in-hospital mortality rate. Discrimination and calibration of risk scores were assessed using the area under the receiver operating characteristic curve (AUC) and calibration plot, respectively. Evaluation of the incremental prognostic value of these markers was done by comparing the AUC between the old and new risk score, and the use of net reclassification improvement (NRI) and integrated discrimination improvement (IDI). RESULTS: Among 192 total patients (median [IQR] age 56 [42-70] years; 114 [59.4%] women), there were 43 (22.4%) who did not survive to discharge. Of the novel inflammatory markers, only red cell distribution width to hemoglobin ratio was significant in predicting in-hospital mortality (odds ratio [OR] 3.55; 95% CI, 1.76-7.16; P < .001) after adjusting for SCORTEN. The RDW/Hb as applied in 4 risk groups showed similar discrimination to SCORTEN (AUC [95% CI]: RDW/Hb in 4 groups, 0.76 [0.69-0.84], vs SCORTEN, 0.78 [0.70-0.85], P = .89). When RDW/Hb was added to SCORTEN, the composite score Re-SCORTEN showed significantly better discrimination than SCORTEN alone (AUC [95% CI]: Re-SCORTEN, 0.83 [0.77-0.89], vs SCORTEN, 0.78 [0.70-0.85], P = .02). The overall NRI was 0.94 (95% CI, 0.68-1.20), P < .001. The IDI was 0.06 (95% CI 0.03-0.08), P < .001. Re-SCORTEN showed good calibration based on the calibration plot. CONCLUSIONS AND RELEVANCE: In this cohort of patients, RDW/Hb, an inexpensive and readily available marker, showed similar predictive accuracy with SCORTEN. Furthermore, when used in combination with SCORTEN, it also helped augment prognostic ability.
引用
- Koh HK, Fook-Chong SMC, Lee HY, et al. Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN). JAMA Dermatol. 2022. PMID: 34935871. doi:10.1001/jamadermatol.2021.5119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。